Prometheus Biosciences, Inc.
NASDAQ: RXDX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark C. McKenna
- Employees
- 97
- Headquarters
- San Diego, United States
- IPO year
- 2021
- Market cap
- $9.6B
- Website
- https://www.prometheusbiosciences.com
Loading RXDX…
Loading profile data…Frequently asked questions about RXDX
What does Prometheus Biosciences, Inc. (RXDX) do?
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing P...
Where does RXDX trade?
Prometheus Biosciences, Inc. (RXDX) trades on the NASDAQ Global Select.
What sector is RXDX in?
Prometheus Biosciences, Inc. (RXDX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prometheus Biosciences, Inc.?
Mark C. McKenna is the chief executive officer of Prometheus Biosciences, Inc. (RXDX).
Where is Prometheus Biosciences, Inc. headquartered?
Prometheus Biosciences, Inc. is headquartered in United States.
Does RXDX pay a dividend?
Prometheus Biosciences, Inc. (RXDX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RXDX go public?
Prometheus Biosciences, Inc. (RXDX) completed its initial public offering in 2021.